Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists

ClyneM.

首页> 外文期刊>Nature reviews. Urology >Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists

【24h】

Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists

机译：前列腺癌：与GnRH激动剂相比，使用GnRH拮抗剂进行ADT的心血管发病风险更低

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

For men with prostate cancer and pre-existing cardiovascular disease, androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) antagonists results in half as many cardiac events-defined as arterial embolic or thrombotic events, haemorrhagic or ischaemic cerebrovascular conditions, myocardial infarction, and other ischaemic heart disease-as treatment with GnRH agonists, according to pooled data from six phase III prospective randomized trials of 2,328 men.

机译：对于患有前列腺癌和既往已有心血管疾病的男性，用促性腺激素释放激素（GnRH）拮抗剂进行的雄激素剥夺疗法（ADT）导致的心脏事件（定义为动脉栓塞或血栓形成事件，出血性或缺血性脑血管疾病，心肌病）减少一半根据GnRH激动剂治疗脑梗死和其他缺血性心脏病的研究，该研究来自对2328名男性进行的六项III期前瞻性随机试验的汇总数据。

著录项

来源
《Nature reviews. Urology》 |2013年第12期|共1页
作者
ClyneM.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists [J] . ClyneM. Nature reviews. Urology . 2013,第12期

机译：前列腺癌：与GnRH激动剂相比，使用GnRH拮抗剂进行ADT的心血管发病风险更低
2. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease [J] . Margel David, Peer Avivit, Ber Yaara, The Journal of Urology . 2019,第6期

机译：随机试验中的心血管发病率比较GNRH激动剂和GNRH拮抗剂在晚期前列腺癌和预先存在的心血管疾病中的患者
3. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease COMMENT [J] . Crawford E. David The Journal of Urology . 2019,第6期

机译：随机试验中的心血管发病率比较GNRH激动剂和GNRH拮抗剂在晚期前列腺癌和预先存在的心血管疾病评论中
4. Novel GnRH Antagonists Derived from Degarelix: Exploration of the GnRH Antagonist Pharmacophore [C] . Manoj P. Samant, Doley J. Hong, Glenn Croston American Peptide Symposium . 2006

机译：来自Degarelix的新型GnRH拮抗剂：探索Gnrh拮抗剂药程
5. Mechanisms of action and effects of chronic high dose exposure to the GnRH agonist deslorelin. [D] . Edwards, Brian S. 2014

机译：长期高剂量暴露于GnRH激动剂deslorelin的作用机理和影响。
6. Editorial Comment: Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease [O] . Felipe Lott 2020

机译：编码评论：随机试验中的心血管发病率比较GNRH激动剂和GNRH拮抗剂在先进前列腺癌和预先存在的心血管疾病中的患者中
7. Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists [O] . Melanie Clyne 2013

机译：与GNRH拮抗剂的心血管发病危险降低，而不是GNRH激动剂

Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists

摘要

著录项

相似文献

相关主题

期刊订阅